Beiersdorf AG Unsponsored ADR (BDRFY)
Beiersdorf Aktiengesellschaft Q2 Earnings Call Highlights
Beiersdorf Aktiengesellschaft ETR: BEI reported a weaker first half of 2026 as continued pressure at NIVEA outweighed growth in its Derma and Healthcare businesses. The company lowered its full-year outlook for its consumer segment and group sales, while outlining an 18-month plan intended to restore NIVEA to sustainable growth.
Beiersdorf: Cutting The Stock In Half Made It A Cautious 'Buy' (Rating Upgrade)
Beiersdorf is now fairly valued after a significant decline, with an intrinsic value estimated at €68.85 per share. Recent results show organic growth of 2.4% in 2025, but Q1 2026 saw a 4.6% organic sales decline, with Nivea under particular pressure. Management maintains flat-to-slightly-positive 2026 guidance, citing Derma segment strength and early signs of Nivea recovery, despite analyst skepticism.
3 Beauty and Cosmetics Stocks to Invest In for Glowing Returns
Beauty stocks continue to shine as a lucrative investment opportunity, driven by consistent growth and innovation in the overall industry. The global cosmetics market is estimated to reach around $661 billion by 2032, increasing from $398 billion in 2023.
